Dr. Jean Hoffman-Censits’ research focus is in urothelial cancers. She has had major roles in trials that have established neoadjuvant ddMVAC as a standard therapy for bladder cancer, and which have led to two FDA approvals of Atezolizumab for bladder cancer. Dr. Jean Hoffman-Censits is co-principal investigator on the first major chemotherapy trial in upper tract cancer and has designed a follow-up trial to test immune checkpoint blockade prospectively in this population. She is designing a program in small cell bladder cancer, a rare but aggressive subtype with little prospective data. She is also designing a clinical and research program focused on women’s bladder cancer; although men outnumber women five to one in bladder cancer incidence, women have a worse prognosis.
Clinical Trial Keywords
Urothelial cancers; Small cell bladder cancer; Women’s bladder cancer
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Pal, SK, Bajorin, D, Dizman, N, Hoffman-Censitis, J, Quinn, D, Petrylak, D, Galsky, M, Vaishampayan, U, De Giorgi, U, Gupta, S, Burris, H, Soifer, H, Li, G, Wang, H, Dambkowski, C, Moran,S Daneshmand, S, Rosenberg, J. “Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Association with Comprehensive Genomic Profiling/Cell-free DNA Results.” Cancer. Accepted for publication, 2020.
Benjamin Miron, MDa, Jean H. Hoffman-Censits, MDb, Fern Anari, MDa, John O'Neilla, Daniel M. Geynisman, MDa, Matthew R. Zibelman, MDa, Alexander Kutikov, MD a, Rosalia Viterbo, MDa, Richard E. Greenberg, MDa, David Chen, MDa, Costas D. Lallas, MDc, Edouard John Trabulsi, MDc, R. Katherine Alpaugh, PhDa, Essel Dulaimi, MDa, Erica A. Golemis, PhDa, Robert Uzzo, MDa, Eric A. Ross, PhDa, Elizabeth R. Plimack, MDa. “Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer.” European Urology Oncology. Accepted for publication, 2020 February.
Hoffman-Censits, J, Choi, W, Pal, S, Trabulsi, E, Kelly, W, Hahn, N, Comperat, E, Matoso, A, Cussenot, O, Cancel-Tassin, G, Fong, M, Ross, J, Madison, R, Ali, S. “Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.” European Urology Oncology. 2020 February.
Vitaly Margulis, MD, Maneka Puligandla, MS, Edouard J. Trabulsi, MD, FACS, Elizabeth R. Plimack, MD, Elizabeth R. Kessler, MD, Surena F. Matin, MD, Guilherme Godoy, MD, Ajjai Alva, MD, Noah M. Hahn, MD, Michael A. Carducci, MD, Jean Hoffman-Censits, MD, and Collaborators. “Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma.” Journal of Urology. 2019 Nov 8.
Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J. “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.” Eur Urol. 2018 May;73(5):800-806.